SCHEMBL7569209

SCHEMBL7569209

Cc1ccc(S(=O)(=O)OC(=NNc2cccc(CNC(=O)OC(C)(C)C)c2)C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.43
CA1 P00915 3/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
GLS O94925 2/20 0.37
CA2 P00918 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.37
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37
PTGER1 P34995 1/20 0.37
NAMPT P43490 1/20 0.36
CYP19A1 P11511 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
BAZ2B Q9UIF8 1/20 0.36
BAZ2A Q9UIF9 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7572499 0.93 CA1 (0.43) BRD4CA1CA12CA7CA14
SCHEMBL7568747 0.86 BRD4 (0.44) BRD4CA1CA12CA7CA14
SCHEMBL2228946 0.78 FFAR1 (0.56) BRD4LMNAALDH1A1MAPT
SCHEMBL7564751 0.78 BRD4 (0.47) BRD4CA1CA12CA7CA14
SCHEMBL2228937 0.78 FFAR1 (0.56) BRD4LMNAALDH1A1MAPT
SCHEMBL2228941 0.78 FFAR1 (0.56) BRD4LMNAALDH1A1MAPT
SCHEMBL7637263 0.75 P2RY2 (0.42) ALDH1A1MAPT
SCHEMBL7568797 0.75 P2RY2 (0.42) ALDH1A1MAPT
SCHEMBL10210711 0.72 BRD4 (0.51) BRD4CA1CA12CA7CA14
SCHEMBL7478429 0.71 BRD4 (0.48) BRD4GLSL3MBTL1AURKARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6465656-B2 ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-10-15 US disclosed
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 US disclosed
US-6329527-B1 ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles TFPI, SERPINC1, F11 BRD4 1251/4885CA1 1253/4885CA12 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.